PMID- 2106403
OWN - NLM
STAT- MEDLINE
DCOM- 19900405
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 81
IP  - 3
DP  - 1990 Mar
TI  - Intravenous thrombolytic therapy with a combination of single-chain 
      urokinase-type plasminogen activator and recombinant tissue-type plasminogen 
      activator in acute myocardial infarction.
PG  - 907-13
AB  - The effects of simultaneous intravenous infusions of 12 mg recombinant 
      tissue-type plasminogen activator (rt-PA) over 30 minutes and 48 mg single-chain 
      urokinase-type plasminogen activator (scuPA) over 40 minutes were studied in 38 
      patients with acute myocardial infarction. Coronary arterial patency was assessed 
      angiographically 60 minutes and 90 minutes after initiation of treatment. Patency 
      was achieved in 19 of 31 patients (61.3%) (95% confidence limits, 42-78%) at 60 
      minutes and in 27 of 33 patients (81.8%) (95% confidence limits, 65-93%) at 90 
      minutes. Nonspecific plasminogen activation was monitored by measuring relevant 
      plasma parameters. At 60 minutes and 120 minutes, the fibrinogen concentration 
      decreased slightly to 82.8 +/- 24.3% and 91.2 +/- 17.4% of the preinfusion level, 
      and the plasminogen concentration to 66.3 +/- 15.2% and 65.3 +/- 13.4%, 
      respectively. A greater consumption of alpha 2-antiplasmin was observed, which 
      decreased to 30.7 +/- 22.8% and 32.2 +/- 21.2% of the preinfusion level at 60 and 
      120 minutes, respectively. No bleeding necessitating transfusion was observed. 
      Two patients (5.3%) died during hospitalization. The findings suggest that the 
      combined intravenous infusion of rt-PA and scuPA at appropriate doses induces 
      highly effective coronary thrombolysis equal to the best results obtained with 
      either rt-PA or scuPA alone. This efficacy is coupled with high specificity. 
      Thus, the data support the potential use of combinations of rt-PA and scuPA in 
      place of monotherapy.
FAU - Bode, C
AU  - Bode C
AD  - Abteilung Innere Medizin III (Kardiologie), Universitat Heidelberg, FRG.
FAU - Schuler, G
AU  - Schuler G
FAU - Nordt, T
AU  - Nordt T
FAU - Schonermark, S
AU  - Schonermark S
FAU - Baumann, H
AU  - Baumann H
FAU - Richardt, G
AU  - Richardt G
FAU - Dietz, R
AU  - Dietz R
FAU - Gurewich, V
AU  - Gurewich V
FAU - Kubler, W
AU  - Kubler W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Enzyme Precursors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - Drug Therapy, Combination
MH  - Enzyme Precursors/therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Plasminogen Activators/*therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - *Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/*therapeutic use
MH  - Urokinase-Type Plasminogen Activator/*therapeutic use
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1161/01.cir.81.3.907 [doi]
PST - ppublish
SO  - Circulation. 1990 Mar;81(3):907-13. doi: 10.1161/01.cir.81.3.907.